Effects of androgen ablation therapy in TRAIL death ligand and its receptors expression in advanced prostate cancer

Urologia Internationalis

Volumn 84, Issue 4, 2010, Pages 445-451

  Koksal, Ismail Turker ^a   Sanlioglu, Ahter Dilsad ^a   Kutlu, Omer ^a   Sanlioglu, Salih ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Androgen ablation therapy; Hormone refractory prostate cancer; Prostate cancer; TRAIL

Indexed keywords

ANTIANDROGEN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; GONADORELIN AGONIST; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; TNFRSF10A PROTEIN, HUMAN; TNFSF10 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR;

ABLATION THERAPY; ADVANCED CANCER; ANTIANDROGEN THERAPY; ARTICLE; CANCER HORMONE THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; TREATMENT RESPONSE; UPREGULATION; CANCER STAGING; DRUG RESISTANCE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS; TIME; TREATMENT OUTCOME; TURKEY;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM STAGING; PROSTATIC NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TREATMENT OUTCOME; TURKEY;

EID: 77953232360     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000304510     Document Type: Article

References (32)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96.
2. Grossmann ME, Huang H, Tindall DJ: Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 2001; 93: 1687-1697.
3. Castilla C, Congregado B, Chinchon D, et al: Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006; 147: 4960-4967.
4. Krajewska M, Krajewski S, Banares S, et al: Elevated expression of inhibitor of apoptosis proteins in prostate cancer. Clin Cancer Res 2003; 9: 4914-4925.
5. Koksal IT, Dirice E, Yasar D, et al: The assessment of PTEN tumor suppressor gene in combination with Gleason scoring and serum PSA to evaluate progression of prostate carcinoma. Urol Oncol 2004; 22: 307-312.
6. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3: 673-682.
7. Ashkenazi A, Pai RC, Fong S, et al: Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 1999; 104: 155-162.
8. Griffith TS, Lynch DH: Trail: A molecule with multiple receptors and control mechanisms. Curr Opin Immunol 1998; 10: 559-563.
9. Emery JG, McDonnell P, Burke MB, et al: Osteoprotegerin is a receptor for the cytotoxic ligand trail. J Biol Chem 1998; 273: 14363-14367.
10. Sheridan JP, Marsters SA, Pitti RM, et al: Control of trail-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277: 818-821.
11. Goodin S, Rao KV, DiPaola RS: State-of-theart treatment of metastatic hormone-refractory prostate cancer. Oncologist 2002; 7: 360-370.
12. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Rep 1966; 50: 125-128.
13. Suzuki H, Ueda T, Ichikawa T, et al: Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 2003; 10: 209-216.
14. Balk SP: Androgen receptor as a target in androgen- independent prostate cancer. Urology 2002; 60: 132-139.
15. Zornig M, Hueber A, Baum W, et al: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001; 1551:F1-F37.
16. Johnstone RW, Ruefli AA, Lowe SW: Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002; 108: 153-164.
17. Sanlioglu AD, Koksal IT, Karacay B, et al: Adenovirus-mediated IKKα KA expression sensitizes prostate carcinoma cells to TRAIL-induced apoptosis. Cancer Gene Ther 2006; 13: 21-31.
18. Aydin C, Sanlioglu AD, Karacay B, et al: Decoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor- related apoptosis-inducing ligand resistance in lung cancer cells. Hum Gene Ther 2007; 18: 39-50.
19. Sanlioglu AD, Dirice E, Aydin C, et al: Surface trail decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cells. BMC Cancer 2005; 5: 54.
20. Sanlioglu AD, Koksal IT, Ciftcioglu A, et al: Differential expression of TRAIL and its receptors in benign and malignant prostate tissues. J Urol 2007; 177: 359-364.
21. Sanlioglu AD, Karacay B, Koksal IT, et al: DcR2 (TRAIL-R4) siRNA and adenovirus delivery of trail (Ad5hTRAIL) breakdown in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther 2007; 14: 976-984.
22. Mahalingam D, Szegezdi E, Keane M, et al: TRAIL receptor signalling and modulation: are we on the right trail? Cancer Treat Rev 2009; 35: 280-288.
23. Deeb DD, Jiang H, Gao X, et al: Chemosensitization of hormone-refractory prostate cancer cells by curcumin to TRAIL-induced apoptosis. J Exp Ther Oncol 2005; 5: 81-91.
24. Leverkus M, Neumann M, Mengling T, et al: Regulation of tumor necrosis factor-related apoptosis-inducing ligand sensitivity in primary and transformed human keratinocytes. Cancer Res 2000; 60: 553-559.
25. Li JH, Kirkiles-Smith NC, McNiff JM, et al: Trail induces apoptosis and inflammatory gene expression in human endothelial cells. J Immunol 2003; 171: 1526-1533.
26. Koschny R, Ganten TM, Sykora J, et al: Trail/ bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007; 45: 649-658.
27. Chen X, Thakkar H, Tyan F, et al: Constitutively active Akt is an important regulator of trail sensitivity in prostate cancer. Oncogene 2001; 20: 6073-6083.
28. Rokhlin OW, Guseva NV, Tagiyev AF, et al: Caspase-8 activation is necessary but not sufficient for tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in the prostatic carcinoma cell line LNCaP. Prostate 2002; 52: 1-11.
29. Rokhlin OW, Taghiyev AF, Guseva NV, et al: TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther 2002; 1: 631-637.
30. Rokhlin OW, Taghiyev AF, Guseva NV, et al: Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005; 24: 6773-6784.
31. Vindrieux D, Reveiller M, Florin A, et al: TNF-α -related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate. J Cell Physiol 2006; 206: 709-717.
32. Koksal IT, Sanlioglu AD, Karacay B, et al: Tumor necrosis factor-related apoptosis inducing ligand-R4 decoy receptor expression is correlated with high Gleason scores, prostate- specific antigen recurrence, and decreased survival in patients with prostate carcinoma. Urol Oncol 2008; 26: 158-165.